Additionally, HER2-targeted therapy patients were far more likely to receive chemotherapy (86.6% vs. 37.8%, p < 0.001) and surgery at the primary tumor site (25.4% vs. 13.1%, p < 0.001). Here, ERBB2 is linked to neoplasm.